about
Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathwaysMolecular targets of TRAIL-sensitizing agents in colorectal cancerTNF superfamily: a growing saga of kidney injury modulators.Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cellsDrug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivativeDeath receptors as targets for anti-cancer therapy.Combined modality therapy with TRAIL or agonistic death receptor antibodies.Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer.Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines.Functional and structural changes in the chinchilla cochlea and vestibular system following round window application of carboplatin.Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effectsEffects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
P2860
Q24810525-11A7CAD9-A00E-40EB-A9A2-4F9D7B66F9D7Q26822382-D950CC55-4359-4766-B087-12979124679CQ30479123-24A15A20-749F-48C0-83B1-D56AF7E2F592Q33921228-93A790A1-1F4D-479E-A070-799C7B2EAC11Q34806765-C92F260F-4DD2-4F49-A9BC-1AE3AAB8A016Q36259724-09E7E2DA-E6AD-43A7-BD83-DE3303B655F7Q36413303-ADD0C4B6-A6C3-4E94-A496-DE20171CF6F3Q37390893-A58A5B98-3A1F-4F26-B901-CE1C7ACF7B98Q37832083-0D6594BA-A72D-4B75-9324-6F6BB523B7EAQ38557486-14B56A5E-9679-498A-9AB7-E5E7504F8639Q39444362-18BC2204-DCDA-4A61-AC90-806A3533DA31Q39711397-6B8B6465-2D9D-40A5-8792-6D27ED45607AQ39784222-43FE5063-CD27-4B2A-B8C2-A79C372BEAE2Q40135330-171E8587-FEDD-46F6-8F9E-73AAF02E2309Q42121311-91579235-D844-4D64-99B0-A3E8144F4655Q42575787-7F012EDB-D1F1-4FA3-AB4E-6B582F712B7AQ55396225-06A84AC1-8242-42D1-AF74-F9839D3C8A17
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
TRAIL and chemotherapeutic drugs in cancer therapy.
@ast
TRAIL and chemotherapeutic drugs in cancer therapy.
@en
type
label
TRAIL and chemotherapeutic drugs in cancer therapy.
@ast
TRAIL and chemotherapeutic drugs in cancer therapy.
@en
prefLabel
TRAIL and chemotherapeutic drugs in cancer therapy.
@ast
TRAIL and chemotherapeutic drugs in cancer therapy.
@en
P2093
P1476
TRAIL and chemotherapeutic drugs in cancer therapy.
@en
P2093
Osamu Ogawa
Xiu-Xian Wu
Yoshiyuki Kakehi
P304
P356
10.1016/S0083-6729(04)67019-1
P577
2004-01-01T00:00:00Z